肾病综合征合并肾静脉血栓应用阿加曲班疗效评价(1)
摘 要：目的 探討肾病综合征合并肾静脉血栓治疗中应用选择性抗凝剂阿加曲班的临床疗效。方法 选择我院2015年3月～2018年2月诊断为肾病综合征合并肾静脉血栓患者56例，采用随机抽样法分为两组，对照组采用低分子肝素抗凝治疗，研究组在对照组治疗基础上联合阿加曲班治疗，记录两组血尿素氮、肌酐、血白蛋白、24 h尿蛋白定量、血小板、纤维蛋白原、甘油三酯结果，进行对比分析。结果 研究组总有效率高于对照组(P<0.05);两组患者治疗后Cr、Upro、ALB、BUN指标较治疗前有改善，研究组改善情况优于对照组(P<0.05)。两组患者治疗前后TG、FIB、PLT无明显变化(P>0.05)。两组患者均未出现与抗凝相关的严重并发症。结论 由于阿加曲班选择性抗凝作用、出血风险小，阿加曲班联合低分子肝素治疗肾病综合征合并肾静脉血栓疗效明显，安全可靠。
关键词：肾病综合征;肾静脉血栓;阿加曲班;低分子肝素;抗凝
中图分类号：R543 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.21.038
, http://www.100md.com
文章编号：1006-1959(2018)21-0135-03
Clinical Efficacy Evaluation of Argatroban in Nephrotic Syndrome with Renal Vein Thrombosis
QIAN Chao-qing1，LIU Miao2，WANG Jia-ping3，YANG Guo-feng4，ZOU Hai-tao4，LIU Yong-dong4，YANG Bai-hui1
(1.Department of Cardiothoracic Surgery，the Second Affiliated Hospital of Kunming Medical University，Kunming 650101，Yunnan，China;
2.Department of Cardiology，the Affiliated Hospital of Jinzhou Medical University，Jinzhou 121001，Liaoning，China;
, 百拇医药
3.Department of Interventional，the Second Affiliated Hospital of Kunming Medical University， Kunming 650101，Yunnan，China;
4.Department of Cardiology，the Second Affiliated Hospital of Kunming Medical University， Kunming 650101，Yunnan，China)
Abstract：Objective To explore the clinical effect of selective anticoagulant Argatroban in the treatment of nephrotic syndrome with renal vein thrombosis. Methods From March 2015 to February 2018 diagnosed with nephrotic syndrome with 56 patients with renal vein thrombosis， divided into two groups by random sampling method， the control group with low molecular heparin anticoagulant therapy，the study group was treated with Argatroban on the basis of the control group.The blood urea nitrogen，creatinine，serum albumin，24 h urine protein quantitation，platelet，fibrinogen and triglyceride results were recorded and compared.Results The total effective rate of the study group was higher than that of the control group (P< 0.05). The indicators of Cr， Upro， ALB and BUN were improved after treatment in the two groups， and the improvement in the study group was better than that in the control group (P< 0.05). There were no significant changes in TG， FIB and PLT before and after treatment (P>0.05). No serious complications related to anticoagulation occurred in both groups. Conclusion The treatment of nephrotic syndrome complicated with renal venous thrombosis with Argatroban is safe and reliable due to its low risk of hemorrhage and selective anticoagulation effect., http://www.100md.com(钱朝庆 刘 淼 王家平 杨国锋 邹海涛 刘永冬 杨百晖)
关键词：肾病综合征;肾静脉血栓;阿加曲班;低分子肝素;抗凝
中图分类号：R543 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.21.038
, http://www.100md.com
文章编号：1006-1959(2018)21-0135-03
Clinical Efficacy Evaluation of Argatroban in Nephrotic Syndrome with Renal Vein Thrombosis
QIAN Chao-qing1，LIU Miao2，WANG Jia-ping3，YANG Guo-feng4，ZOU Hai-tao4，LIU Yong-dong4，YANG Bai-hui1
(1.Department of Cardiothoracic Surgery，the Second Affiliated Hospital of Kunming Medical University，Kunming 650101，Yunnan，China;
2.Department of Cardiology，the Affiliated Hospital of Jinzhou Medical University，Jinzhou 121001，Liaoning，China;
, 百拇医药
3.Department of Interventional，the Second Affiliated Hospital of Kunming Medical University， Kunming 650101，Yunnan，China;
4.Department of Cardiology，the Second Affiliated Hospital of Kunming Medical University， Kunming 650101，Yunnan，China)
Abstract：Objective To explore the clinical effect of selective anticoagulant Argatroban in the treatment of nephrotic syndrome with renal vein thrombosis. Methods From March 2015 to February 2018 diagnosed with nephrotic syndrome with 56 patients with renal vein thrombosis， divided into two groups by random sampling method， the control group with low molecular heparin anticoagulant therapy，the study group was treated with Argatroban on the basis of the control group.The blood urea nitrogen，creatinine，serum albumin，24 h urine protein quantitation，platelet，fibrinogen and triglyceride results were recorded and compared.Results The total effective rate of the study group was higher than that of the control group (P< 0.05). The indicators of Cr， Upro， ALB and BUN were improved after treatment in the two groups， and the improvement in the study group was better than that in the control group (P< 0.05). There were no significant changes in TG， FIB and PLT before and after treatment (P>0.05). No serious complications related to anticoagulation occurred in both groups. Conclusion The treatment of nephrotic syndrome complicated with renal venous thrombosis with Argatroban is safe and reliable due to its low risk of hemorrhage and selective anticoagulation effect., http://www.100md.com(钱朝庆 刘 淼 王家平 杨国锋 邹海涛 刘永冬 杨百晖)